5 stories found
Jasper Therapeutics exceeded its second-quarter earnings expectations, with GAAP EPS beating forecasts. Despite the positive earnings, the company's stock fell by 4% after the results were announced.
Innventure announced its financial results, with a GAAP EPS of -$5.39, missing analyst estimates by $0.14, and reported revenue of $2.1 million.
Jasper Therapeutics reported a GAAP EPS of -$0.04, significantly beating analyst estimates by $0.48, indicating a stronger financial performance than anticipated.
UBS has begun its coverage of Jasper Therapeutics (JSPR) with a 'Neutral' rating, despite acknowledging progress in the company's drug Briquilimab.